Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pregestational diabetes (PGD) during pregnancy may be associated with an increased rate of spontaneous abortions, intrauterine death and congenital anomalies among the offspring. Although the prevalence of congenital anomalies among the offspring of diabetic mothers is reduced as a result of the improvement of the glycemic control in the early pregnancy, the rate of congenital anomalies is increased and there seems to be an increased rate of neurodevelopmental disorders including some fine and gross motor deficits as well as increased rate of inattention and/or hyperactivity. In gestational diabetes, that develops in the second half of pregnancy (past the period of major organogenesis), there seems to be no increase in the rate of major congenital anomalies but there are some developmental disorders in the offspring.
The exposure of the developing embryo and fetus to diabetic environment (i.e. hyperglycemia, hyperketonemia ext), is known to cause increased oxidative stress and significant changes in gene expression as observed in several experimental diabetic models. We hypothesize that diabetic environment may also cause long lasting epigenetic changes. It is therefore our purpose to evaluate these possible epigenetic changes and correlate their presence with the degree and time of onset of diabetes, (i.e. whether from the beginning as in PGD or in the second half of pregnancy as in GD), the degree of oxidative stress and with the neurodevelopmental outcome of the offspring. Diabetic pregnancies will be compared to a similar number of normal pregnancies in all parameters studied.
| Condition |
|---|
|
Gestational Diabetes Pregestational Diabetes IDM (Infant of Diabetic Mothers) Neurodevelopmental Outcome Epigenetic Changes |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes: Molecular Studies of the Placenta and Cord Blood and Possible Correlation to Postnatal Development. |
Placental biopsy cord bloos Saliva
| Estimated Enrollment: | 300 |
| Study Start Date: | December 2010 |
| Groups/Cohorts |
|---|
|
Non Diabetic-Controls
Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
|
|
Diabetic Pregnancy
Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Infants of diabetic mothers. The follow-up will start at the high risk pregnancy clinic. The obstetrician will follow women with pre-gestational and gestational diabetes. The neonates will be evaluated and followed for epigenetic changes and neurodevelopmental outcome
Inclusion Criteria:
- Infants born to women suffering from pre-gestational or gestational diabetes.
Exclusion Criteria:
- Non Jewish population
- Triplets and up
- Premature infants under 32 weeks
- Infants suffering from major congenital anomalies
- Infants with chromosomal aberrations
Contacts and Locations| Contact: Asher Ornoy, MD | 0097226758329 | ornoy@cc.huji.ac.il |
| Contact: Zivanit Ergaz Shaltiel, MD | 00972507874285 | zivanit@hadassah.org.il |
| Israel | |
| Hadassah Medical Organization, Jerusalem, Israel | Not yet recruiting |
| Jerusalem, Israel | |
| Contact: Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il | |
| Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il | |
| Principal Investigator: Asher Ornoy, MD | |
| Principal Investigator: Zivanit Ergaz shaltiel, MD | |
| Sub-Investigator: Drorit Hochner, MD | |
| Sub-Investigator: Simcha Yagel, MD | |
| Sub-Investigator: Uri Elchalal, MD | |
| Study Director: | Asher Ornoi, MD | Hadassah Medical Organization |
More Information
No publications provided
| Responsible Party: | Prof. Asher Ornoy, Laboratory of Teratology, Israel Canada Institute of Medical Research, Hebrew University Hadassah Medical School, Jerusalem, Israel. |
| ClinicalTrials.gov Identifier: | NCT01255384 History of Changes |
| Other Study ID Numbers: | EPI-DIABETES-HMO-CTIL |
| Study First Received: | December 6, 2010 |
| Last Updated: | December 6, 2010 |
| Health Authority: | Israel: Ministry of Health |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes, Gestational Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Pregnancy Complications |
ClinicalTrials.gov processed this record on June 18, 2013